ORIC Oric Pharmaceuticals
- 9.310
- +0.220+2.42%
- 9.310
- 0.0000.00%
Oric Pharmaceuticals News
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne
Buy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical Pipeline
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Oric Pharmaceuticals Is Maintained at Buy by Citigroup
Oric Pharmaceuticals Is Maintained at Buy by Citigroup
Oric Pharmaceuticals Price Target Cut to $14.00/Share From $15.00 by Citigroup
Oric Pharmaceuticals Price Target Cut to $14.00/Share From $15.00 by Citigroup
Citi: Maintains ORIC Pharmaceuticals (ORIC.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $14.00.
Citi: Maintains ORIC Pharmaceuticals (ORIC.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $14.00.
Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $14
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals with a Buy and lowers the price target from $15 to $14.
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)
Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Clinical Data and Strong Financial Position
Oric Pharmaceuticals | 10-Q: Quarterly report
ORIC Pharmaceuticals Q1 EPS $(0.37) Beats $(0.51) Estimate
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.51) by 27.45 percent. This is a 30.19 percent increase over losses of
Oric Pharmaceuticals 1Q Loss/Shr 37c >ORIC
Oric Pharmaceuticals 1Q Loss/Shr 37c >ORIC
Press Release: ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients With Mutated NSCLC
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
ORIC Pharmaceuticals Presents Preclinical Data On Two Programs At The 2024 AACR Annual Meeting
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors.
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
Oric Pharmaceuticals Bolsters Incentive Plan to Attract Talent
Analysis
Price Target
No Data
